Login to Your Account

MTM Adds $15M to Series C for Biomarker-based Assays

By Cormac Sheridan

Wednesday, April 23, 2008
MTM Laboratories AG added another E9.6 million (US$15.3 million) to its Series C financing round, taking the total to E31.6 million and giving the company additional funds for further clinical development of its biomarker-based diagnostic assays for cervical cancer and for building out its sales and marketing infrastructure. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription